Biolargo Inc.
BLGOBiolargo Inc. in brief
Biolargo Inc. is a listed company in the Chemicals industry, based in Westminster, California, USA. Its market value was $32 M on 1 August 2026, which makes it the 22,792nd largest listed company in the world and the 4,023rd largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $15 M. It employs about 46 people. Its largest business segments by sales in 2025 were Odor-No-More (76%), BioLargo Engineering, Science & Technologies, LLC (33%) and BioLargo Canada (1%).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Biolargo Inc.
BioLargo, Inc. is a corporation organized under the laws of the state of Delaware. Our common stock is quoted on the OTC Markets highest level marketplace, the OTCQX, under the trading symbol “BLGO”.
Our corporate offices are located at 14921 Chestnut St., Westminster, California 92683. We have a research facility and offices at the University of Alberta in Canada, and our engineering team is located at 105 Fordham Road in Oak Ridge, Tennessee. Our medical products company is located at 10770 N. 46th Street, Unit C-300, in Tampa, Florida. Our telephone number is (888) 400-2863. We operate through multiple wholly- and partially-owned subsidiaries.
From the company's annual report filed with the US SEC: read the report
Biolargo Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2001
- ✎Renamed Nuway Energy IncFormerly Latin American Casinos Inc.
- 2003
- ✎Renamed Nuway Medical IncFormerly Nuway Energy Inc.
- 2007
- ✎Renamed Biolargo, Inc.Formerly Nuway Medical Inc.
- 2024
- 💰Record revenue of $18 millionFY2024, the highest of the 8 years on record.
Events of Biolargo Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,885 (Jan 2022) · #4,814 (Dec 2022) · #4,697 (Jul 2023) · #3,859 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 7.9×
- Price / book
- 7.9×
- Free cash flow yield
- -13.5%
- Net margin (TTM)
- -377.6%
- Operating margin
- -191.5%
- Return on equity
- -380.4%
- Liabilities / assets
- 81.6%
- Net debt
- $-2M
- Revenue growth
- -56.4%
- R&D / revenue
- 33.4%
- Revenue per employee
- $169 K
- Profit per employee
- $-330 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $8M | -56.4% | $-15M | $-15M | -195.7% |
| Dec 2024 | $18M | +45.4% | $-4M | $-4M | -24.5% |
| Dec 2023 | $12M | +108.0% | $-5M | $-5M | -38.0% |
| Dec 2022 | $6M | +132.4% | $-5M | $-5M | -87.2% |
| Dec 2021 | $3M | +4.1% | $-7M | $-7M | -272.3% |
| Dec 2020 | $2M | +30.6% | $-8M | $-10M | -399.2% |
| Dec 2019 | $2M | +36.8% | $-7M | $-11M | -615.1% |
| Dec 2018 | $1M | — | $-6M | $-11M | -786.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | — | — | — | — |
| Dec 2024 | $-3M | — | — | — | — |
| Dec 2023 | $-2M | — | — | — | — |
| Dec 2022 | $-3M | — | — | — | — |
| Dec 2021 | $-4M | — | — | $-0.03 | — |
| Dec 2020 | $-4M | — | — | $-0.05 | — |
| Dec 2019 | $-4M | — | — | $-0.08 | — |
| Dec 2018 | $-4M | — | — | $-0.09 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-0.9% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 16, 202610-QQuarterly report · period to Sep 2026
- Nov 2, 20268-KCurrent reportRegulation FD disclosure
- Oct 19, 2026DEF 14AProxy statement
- Sep 14, 20268-K/ACurrent report (amended)Regulation FD disclosure
- Sep 11, 20268-KCurrent reportRegulation FD disclosure
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportRegulation FD disclosure
- May 4, 20268-KCurrent reportRegulation FD disclosure
- Apr 30, 202610-K/AAnnual report (amended) · period to Dec 2025
- Apr 17, 2026424B4IPO prospectus
- Apr 17, 2026424B4IPO prospectus
Official filings of Biolargo Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $8 M
- Operating income
- $-15 M
- Net income
- $-15 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $7 M
- Total equity
- $4 M
As of December-2025
Top 1 institutional investors in Biolargo Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | First American Trust, FSB | 117,838 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
Insider trading at Biolargo Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Dennis P. CalvertPresident, Director | Grant or award | +931,886 | $0.080 | $75 K | 11.99 M | Form 4 |
| filed | Kenneth Reay CodeChief Science Officer, Director | Grant or award | +566,261 | $0.080 | $45 K | 26.97 M | Form 4 |
| filed | Dennis P. CalvertPresident, Director | Gift | +2.00 M | — | — | 13.99 M | Form 4 |
| filed | Kenneth Reay CodeChief Science Officer, Director | Gift | -2.00 M | — | — | 24.97 M | Form 4 |
| filed | Kenneth Reay CodeChief Science Officer, Director | Grant or award | +532,567 | $0.110 | $59 K | 26.41 M | Form 4 |
| filed | Dennis P. CalvertPresident, Director | Grant or award | +219,914 | $0.110 | $24 K | 11.06 M | Form 4 |
| filed | Dennis P. CalvertPresident, Director | Grant or award | +699,569 | $0.110 | $77 K | 10.84 M | Form 4 |
| filed | Kenneth Reay CodeChief Science Officer, Director | Grant or award | +69,444 | $0.160 | $11 K | 25.88 M | Form 4 |
Biolargo Inc. scorecard#
Passes 6 of the 16 checks that could be worked out: strongest in growth (3 of 5), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
Growth3 of 5
Profitability0 of 5
Financial health3 of 6
Shareholder returnsnot known
Worked out from the statements as filed (sec), the medians of Chemicals, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Biolargo Inc.'s statements, beside the median of Chemicals.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -191.5% | 4.7% | |
| Net margin | -195.8% | 2.2% | |
| Return on equity | -235.7% | 2.1% | |
| Revenue growth, 3 years a year | 9.7% | -2.4% | |
| Revenue growth | -56.4% | 0.4% | |
| Debt to equity | 0.51× | 0.64× |
1of 8on the Piotroski tests of financial strength
- Revenue fell 56.4% against the year before.
- Net loss of $15 million, the 16th loss-making year in a row.
- Operating income covers the interest bill only -27.5 times.
- More cash than debt: net cash of $2 million.
Biolargo Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 7.8 | 18 | 12 | 5.9 | 2.5 | 2.4 | 1.9 | 1.4 | 0.5r | 0.3 | |
| Cost of revenue | 4.4 | 9.9 | 6.1 | 3.0 | 1.4 | 1.2 | 0.9 | 0.7 | 0.3r | 0.1 | |
| Gross profit | 3.4 | 7.9 | 6.2 | 2.9 | 1.1 | 1.2 | 0.9 | 0.6 | 0.2r | 0.2 | |
| Research and development | 2.6 | 2.9 | 2.3 | 1.3 | 1.4 | 1.3 | 1.5 | 1.7 | 1.6r | 1.4 | |
| Selling, general and administrative | 12 | 9.3 | 8.1 | 6.7 | 6.2 | 7.5 | 6.1 | 5.3r | 4.4r | 3.7 | |
| Operating expenses | 18 | 12 | 11 | 8.2 | 7.9r | 8.8 | 7.6 | 7.0 | 6.1 | — | |
| Operating income | −15 | −4.3 | −4.6 | −5.4 | −6.8r | −7.6 | −6.7 | −6.4 | −5.9r | −4.9 | |
| Interest and finance income | 0.2 | 0.0r | — | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 0.5 | 0.1r | 0.1 | 0.1 | 0.2 | 1.9 | 4.0 | 3.5 | 3.9r | 3.1 | |
| Net interest income | −0.3 | −0.0 | −0.1 | −0.1 | — | — | — | — | — | — | |
| Share of profit of associates | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | — | — | — | — | |
| Other non-operating income (expense) | −0.3 | −0.0 | −0.1 | 0.3 | −0.1r | −2.1 | −4.7 | −4.3 | −3.7r | −3.1 | |
| Income before tax | −15 | −4.3 | — | — | — | — | — | — | — | — | |
| Income tax | — | 0 | 0 | — | — | — | — | — | — | — | |
| Net income including minority interests | −15 | −4.3 | −4.6 | −5.1 | −6.9 | −9.7 | −11 | −11 | −9.5r | −8.1 | |
| Minority interests' share of net income | −3.4 | −1.9 | −1.1 | −0.7 | 0.2 | — | — | — | — | −0.2 | |
| Earnings per share, basic | -0.04 | -0.01 | -0.01r | -0.02 | -0.03 | -0.05 | -0.08 | -0.09 | -0.10 | -0.09 | |
| Earnings per share, diluted | — | — | — | — | -0.03 | -0.05 | -0.08 | -0.09 | -0.10 | -0.09 | |
| Shares, weighted average (basic) | 307 | 298 | 286 | 268 | 247 | 196 | 152 | 122 | 99 | 88 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.9 | 3.5 | 3.5 | 1.9 | 1.0 | 0.7 | 0.7 | 0.7 | 1.0r | 1.9r | |
| Receivables | 0.6 | 3.2 | 2.6 | 1.1 | 0.5 | 0.5 | 0.4 | 0.3 | 0.1r | 0.1 | |
| Inventory | 0.3 | 0.3 | 0.2 | 0.1r | 0.2 | 0.3 | 0.0 | 0.0 | 0.1r | 0.0 | |
| Other current assets | 0.3 | 0.1 | 0.1 | 0.1r | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Current assets | 5.1 | 7.1 | 6.4 | 3.2 | 1.8 | 1.5 | 1.1 | 1.0 | 1.2r | 2.0 | |
| Property, plant and equipment | 1.6 | 1.7 | 0.7 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1r | 0.1 | |
| Right-of-use (leased) assets | 1.0 | 1.0 | 1.1 | 0.9 | 0.5 | 0.3 | 0.4 | — | — | — | |
| Other intangible assets | — | — | — | 4.9 | 3.0r | 2.2 | 1.9 | 1.9 | — | — | |
| Investments in associates | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | — | — | — | — | |
| Non-current assets | — | — | — | — | 1.2 | 3.4 | — | — | — | — | |
| Total assets | 8.3 | 11 | 8.2 | 4.9 | 3.0 | 4.9 | 3.6 | 3.2 | 1.5r | 2.1 | |
| Accounts payable | 1.0 | 0.8 | 1.2 | 0.7 | 0.4 | 0.3 | 0.2r | 0.3 | 0.1r | 0.0 | |
| Debt due within a year | — | 0.1r | 0.1 | 0.1 | 0.3 | 1.2r | 4.1r | 2.2 | 5.2r | 0.6r | |
| Current liabilities | 5.1 | 2.6 | 2.7 | 1.6 | 1.4 | 3.5 | 4.4 | 2.5 | 4.2r | 1.2 | |
| Long-term debt | — | — | 0.3 | 0.2 | 0.2 | 0.5 | 0.7 | 1.3 | 1.5r | 5.3 | |
| Lease liabilities (non-current) | 0.9 | 0.9 | 1.0 | 0.8 | 0.3 | 0.2 | 0.3r | — | — | — | |
| Non-current liabilities | 1.7 | 1.8 | 1.3 | 1.3 | 0.7 | 1.6 | — | 1.8 | — | — | |
| Total liabilities | 6.8 | 4.5 | 4.0 | 2.8 | 2.1 | 5.2 | 5.8 | 4.3 | 4.9r | 2.9 | |
| Retained earnings | −161 | −150 | −147 | −144 | −139 | −132 | −123 | −112 | −101r | −92 | |
| Shareholders' equity | 4.0 | 8.9 | 6.8 | 4.9 | 4.7 | 3.9 | −2.2 | −1.5 | −4.1r | −1.3 | |
| Minority interests | −2.5 | −2.8 | −2.6 | −2.9 | −3.7 | −4.1 | −0.0 | 0.4 | 0.7r | 0.6 | |
| Total equity | 1.5 | 6.1 | 4.2 | 2.0 | 0.9 | −0.2 | −2.2 | −1.1 | −3.4r | −0.8r | |
| Total liabilities and equity | 8.3 | 11 | 8.2 | 4.9 | 3.0 | 4.9 | 3.6 | 3.2 | 1.5r | 2.1 | |
| Shares outstanding | — | — | 293 | 278 | — | — | 166 | — | — | 93 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0r | 0.0 | |
| Share-based compensation | 3.0 | 2.1 | 2.1 | 2.1 | 1.9 | 2.5 | 1.5 | 1.3 | 1.1r | 0.8 | |
| Cash from operating activities | −8.3 | −3.2 | −2.4 | −2.8 | −3.9 | −4.2 | −4.4 | −3.9 | −4.3r | −3.7 | |
| Capital expenditure | — | — | — | — | — | — | — | — | −0.0 | — | |
| Intangible assets bought | — | — | — | 0 | −0.0 | 0 | — | — | — | — | |
| Cash from investing activities | 0.4 | −1.3 | −0.5 | −0.3 | −0.0 | −0.1 | −0.0 | −0.1 | −0.0r | −0.1 | |
| Shares issued | 2.0 | 0.6 | 2.2 | 3.6 | 4.9 | 2.8 | 0.1 | 0.8 | 0.5r | — | |
| Cash from financing activities | 8.2 | 4.4 | 4.7 | 4.0 | 4.2 | 4.3 | 4.5 | 3.6 | 3.4r | 4.0 | |
| Exchange-rate effect on cash | — | — | — | — | — | — | −0.0 | −0.0 | 0.0r | −0.0 | |
| Change in cash | 0.3 | 0.0 | 1.7 | 0.9 | 0.2 | 0.1 | — | −0.3 | −0.9r | 0.1 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Jun 30, 2026
What Biolargo Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$6 M74%-66%
- Service(total)$2 M26%+96%
Business segments
- Odor-No-More$6 M76%-62%
- BioLargo Engineering, Science & Technologies, LLC$3 M33%-21%
- BioLargo Canada$0 M1.1%+29%
As of Dec 31, 2025
Executive pay at Biolargo Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $318 K | $318 K | $252 K | $90 |
| 2024Chief executive | $318 K | $318 K | $266 K | $90 |
| 2023Chief executive | $317 K | $299 K | $215 K | $79 |
As of Dec 31, 2025
Events at Biolargo Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- ImpairmentFiling
Impairment 1 · Material agreement 1 · Agreement ended 1 · Unregistered share sale 1 · Shareholder vote 2
As of Mar 25, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Lobbying by Biolargo Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
J.A. Green and Company (formerly LLC) $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2025 | $20 K | — | 2 |
| 2024 | $80 K | — | 4 |
| 2023 | $30 K | — | 2 |
How Biolargo Inc. compares in Chemicals
- Market cap$32 M · higher than 16% of 1,115
- Revenue$8 M · higher than 3% of 421
- Net margin-377.6% · higher than 0% of 409
- Revenue growth-56.4% · higher than 4% of 111
- Price / sales7.9× · lower than 11% of 382
- Price / book7.9× · lower than 11% of 345
- FCF yield-13.5% · higher than 13% of 80
Peer comparison · Chemicals
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Biolargo Inc.🇺🇸 | $32 M | — | -377.6% | -56.4% |
| Linde plc🇬🇧 | $231.0 B | 33.0× | 19.3% | +3.0% |
| Air Liquide🇫🇷 | $124.8 B | 29.9× | 13.1% | +3.8% |
| The Sherwin-Williams Company🇺🇸 | $81.4 B | 30.4× | 10.7% | +2.1% |
| Ecolab Inc.🇺🇸 | $79.7 B | 38.3× | 12.0% | +2.2% |
| Shin-Etsu Chemical Co., Ltd.🇯🇵 | $74.3 B | 23.1× | 18.4% | — |
| Air Products and Chemicals, Inc.🇺🇸 | $66.5 B | 125.0× | 4.1% | +7.9% |
| BASF SE🇩🇪 | $52.7 B | 27.4× | 2.7% | -18.8% |
| Nan Ya Plastics Corporation🇹🇼 | $49.7 B | 336.2× | 1.7% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
How current the figures are
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 2, 2026
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Biolargo Inc.? Verify and update this profile — free
Show Biolargo Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.